Skip to main content

Table 4 Reference point dose difference between pre- and post-CE, compared with the average change of effective depth

From: Dosimetric effect of CT contrast agent in CyberKnife treatment plans

Case No. Target Mean deffdifference Reference point dose
In RT In MC
1 Lung (Left Lower Lobe) 11.4 mm 6.2% 3.8%
2 Lt. Pleura 11.0 mm 5.7% 4.0%
3 Lung (Left Upper Lobe) 7.4 mm 3.3% 2.4%
4 T4 6.4 mm 2.7% 3.8%
5 Liver (Segment 6) 4.7 mm 2.7% 3.0%
6 PAN* 5.2 mm 2.4% 0.2%
7 Lung (Left Upper Lobe) 4.1 mm 2.1% 1.7%
8 L2 3.9 mm 2.1% 1.9%
9 SMA LN 3.7 mm 1.9% 1.7%
10 Liver (Segment 8) 3.2 mm 1.6% 1.1%
11 T1-2 3.1 mm 1.5% 1.0%
12 L2-5§ 3.6 mm 1.3% 2.1%
13 Lung (Right Middle Lobe) 2.6 mm 1.2% 1.3%
14 Iliac LN 2.0 mm 1.1% 0.6%
15 Lt. Kidney (Renal Pelvis) 4.4 mm 1.0% 1.2%
16 Prostate 1.2 mm 0.8% 1.1%
17 C5|| 1.5 mm 0.7% 1.1%
18 C5-T2 3.1 mm 0.6% 0.5%
19 Prostate 1.2 mm 0.6% 0.7%
20 Prostate 1.6 mm 0.6% 1.1%
21 Prostate 1.1 mm 0.5% 0.4%
22 Prostate 1.1 mm 0.4% 0.9%
  Average ± 1SD 4.0 ± 2.9 mm 1.9 ± 1.6% 1.6 ± 1.1%
  1. *PAN : Paraaortic lymph node.
  2. SMA LN : Superior mesenteric artery lymph node.
  3. T : Thoracic spine.
  4. §L : Lumbar spine.
  5. ||C : Cervical spine.